Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12

By Bernstein D.I.   Smith V.E.   Sherwood J.R.   Schiff G.M.   Sander D.S.   DeFeudis D.   Spriggs D.R.   Ward R.L.  

Vaccine, Vol. 16, Iss. 4, 1998-02 ,pp. : 381-387

Elsevier

Access to resources Recommend Favorite

Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response

By Wyeth-Ayerst ca Influenza Vaccine Study Group   Gruber W.C.   Darden P.M.   Still J.G.   Lohr J.   Reed G.   Wright P.F.  

Vaccine, Vol. 15, Iss. 12, 1997-08 ,pp. : 1379-1384

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants

By Clements-Mann M.L.   Dudas R.   Hoshino Y.   Nehring P.   Sperber E.   Wagner M.   Stephens I.   Karron R.   Deforest A.   Kapikian A.Z.  

Vaccine, Vol. 19, Iss. 32, 2001-09 ,pp. : 4676-4684

Elsevier

Access to resources Recommend Favorite

Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon- production and local IgA response

By Tomoda T.   Morita H.   Kurashige T.   Maassab H.F.  

Vaccine, Vol. 13, Iss. 2, 1995-02 ,pp. : 185-190

Elsevier

Access to resources Recommend Favorite

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control

By Longini I.M.   Halloran M.E.   Nizam A.   Wolff M.   Mendelman P.M.   Fast P.E.   Belshe R.B.  

Vaccine, Vol. 18, Iss. 18, 2000-03 ,pp. : 1902-1909

Elsevier

Access to resources Recommend Favorite